Q2 2024 Bionano Genomics Inc Earnings Call Transcript
Key Points
- Bionano Genomics Inc (BNGO) received approval for a Category 1 CPT code for optical genome mapping, which is expected to significantly increase adoption and utilization.
- The OGM installed base grew to 363 systems, representing a 29% growth over the previous year.
- The company entered a Software Marketing Agreement with Revvity, enhancing its market presence and potential revenue streams.
- Publications related to Bionano's technology increased by 37% in the first half of 2024 compared to the same period in 2023, indicating growing academic and clinical interest.
- Bionano reported a significant reduction in operating expenses, with a 46% decrease in non-GAAP operating expenses compared to the previous year.
- Revenue for Q2 2024 was $7.8 million, a 10% year-over-year decrease, partly due to a 53% reduction in revenues from discontinued clinical services.
- The number of flow cells sold decreased by 13% year-over-year, marking the first decline in 20 consecutive quarters.
- Underperformance in China due to OEM partners and key customers falling behind on purchases, with an estimated shortfall of 1,200 flow cells.
- Challenges in the Americas region due to the transition from Saphyr to Stratys systems and reduced field sales and support teams.
- The company adjusted its full-year 2024 revenue guidance downwards to $36 million to $40 million, citing challenges in China and other regions.
Good day, and thank you for standing by. Welcome to the Bionano Q2 financial results call. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, David Holmes, Investor Relations. Please go ahead.
Thank you, operator, and good afternoon, everyone. Welcome to the Bionano second quarter 2024 financial results conference call. Leading the call today is Dr. Erik Holmlin, CEO of Bionano. He is joined by Gulsen Kama, CFO of Bionano.
After market closed today, Bionano issued a press release announcing its financial results for the second quarter of 2024. A copy of the release can be found on the Investor Relations page of the company's website.
Certain statements made during this conference call may be forward-looking statements, including statements about Bionano's revenue outlook, profitability, cash runway, cost savings initiatives and commercialization and product plans. Such statements
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
